Coronavirus Update: RedHill’s Opaganib Fails As Company Accelerates RHB-107 Study
Plus, New Data From Pharming, CalciMedica
The Israeli biotech announced disappointing Phase II/III data for opaganib while expanding its Phase II/III RHB-107 study. Pharming unveiled promising data from a company-sponsored study, but an imbalance in an investigator-led study confounded results, while CalciMedica built on the case for its drug as a treatment for COVID-19 pneumonia.
You may also be interested in...
More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron.
Emergex is preparing to begin a Phase I study of its T-cell priming vaccine, RedHill BioPharma has completed enrolment in a Phase II/III study of upamostat, and Australia is assessing Moderna’s Spikevax for use in 6-11 year olds.
Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?